Harrow (NASDAQ:HROW) and Merck KGaA (OTCMKTS:MKKGY) Critical Survey

Merck KGaA (OTCMKTS:MKKGY – Get Free Report) and Harrow (NASDAQ:HROW – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability.

Volatility and Risk

Merck KGaA has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500. Comparatively, Harrow has a beta of 0.18, meaning that its stock price is 82% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for Merck KGaA and Harrow, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Merck KGaA 0 6 0 0 2.00
Harrow 2 1 6 0 2.44

Harrow has a consensus target price of $66.20, suggesting a potential upside of 117.69%. Given Harrow’s stronger consensus rating and higher possible upside, analysts plainly believe Harrow is more favorable than Merck KGaA.

Earnings and Valuation

This table compares Merck KGaA and Harrow”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Merck KGaA $23.87 billion 0.86 $2.95 billion $1.37 23.24
Harrow $272.30 million 4.19 -$5.14 million ($0.78) -38.99

Merck KGaA has higher revenue and earnings than Harrow. Harrow is trading at a lower price-to-earnings ratio than Merck KGaA, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Merck KGaA and Harrow’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Merck KGaA 8.95% 6.53% 3.68%
Harrow -9.39% -69.81% -5.16%

Institutional & Insider Ownership

0.1% of Merck KGaA shares are owned by institutional investors. Comparatively, 72.8% of Harrow shares are owned by institutional investors. 12.8% of Harrow shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Merck KGaA beats Harrow on 7 of the 13 factors compared between the two stocks.

About Merck KGaA

(Get Free Report)

Merck KGaA is a German science and technology company headquartered in Darmstadt. Founded in 1668, it traces its origins to a pharmacy established by the Merck family and has grown into a global business serving customers in healthcare, research and industry. It is separate from the U.S.-based Merck & Co. The company operates through three main businesses. Its Healthcare division develops and markets prescription medicines, including treatments in areas such as oncology, neurology and fertility.

About Harrow

(Get Free Report)

Harrow is a pharmaceutical company focused on developing, acquiring and commercializing treatments for eye conditions. Its portfolio includes prescription ophthalmic medicines used in areas such as dry eye disease, eye inflammation and pain management, as well as products used in eye surgery and clinical settings. The company markets branded products including VEVYE, a treatment for dry eye disease, and IHEEZO, an ophthalmic anesthetic gel. Through its ImprimisRx subsidiary, Harrow also provides compounded medications and related services for ophthalmology practices and patients.

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.